Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance
 Viracta Therapeutics, Inc., a precision oncology company primarily focused on targeting virus-associated malignancies, announced that the Company has entered into a loan and security agreement with Silicon Valley Bank (SVB) and Oxford Finance LLC (Oxford) for up to $50.0 million. In connection with the $50.0 million credit facility, the Company and SVB......